TFFP News and Press, TFF Pharmaceuticals Inc - Ordinary Shares From 06/22/21

MENLO PARK, Calif. and AUSTIN, Texas, June 22, 2021 (GLOBE NEWSWIRE) -- Augmenta Bioworks, a biotechnology company enabling breakthroughs in medicine through immune profiling, and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and ...

Focus on TFF Tacrolimus for Lung Transplant and TFF in Vaccine Technology Tuesday, June 15 th @ 4pm ET AUSTIN, Texas, June 07, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developi...

TFFP has a thin-film technology that produces inhalable powdered forms of common drugs, with various advantages over existing methods. They have two assets in the clinic, with upcoming pivotal trials. Current depressed prices are a result of catalyst desert and look attractive. ...

I began investing seriously at the end of 2019 and have since begun researching stocks full time. After traversing 2020, I have already learned much about the market and how to move forward. This article will highlight what I believe is close to a well-rounded portfolio for the co...

AUSTIN, Texas, May 25, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced th...

TFF Pharmaceuticals (NASDAQ: TFFP) , a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (“TFF”) technology platform, announced that it has closed on its recent underwritten offe...

Image source: The Motley Fool. TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) Q1 2021 Earnings Call May 13, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: TFF Pharmaceuticals, Inc. (TFFP) Q1 2021 Earnings Call Transcript...

TFF Pharmaceuticals Inc. (TFFP) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Paul Sagan – Investor Relations Glenn Mattes – President, Chief Executive Officer and Director Dale Christensen – Director-Clinical Development Kirk Coleman ...

TFF Pharmaceuticals (TFFP): Q1 GAAP EPS of -$0.33 misses by $0.09.Revenue of $0.02MCash and cash equivalents of $58.06MPress Release For further details see: TFF Pharmaceuticals EPS misses by $0.09

Pivotal Trials to Begin in 2H-2021 for Voriconazole Inhalation Powder for the Treatment of Invasive Pulmonary Aspergillosis (IPA) and Tacrolimus Inhalation Powder for Immunosuppression in Solid Organ Transplantation Patent Filed for Once-a-Day Dosing for Tacrolimus Inhalation ...